Tirzepatide is a novel dual receptor agonist targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This pharmaceutical grade peptide demonstrates significant potential in metabolic research applications.
The compound shares structural similarities with semaglutide but features a unique PEG modification that enhances its water solubility and biological activity. As a dual agonist, tirzepatide combines the effects of two important incretin hormones in a single molecule, making it particularly interesting for metabolic disorder research.
Research studies have demonstrated tirzepatide's potential effects in glucose regulation and weight management. The peptide appears to work through multiple mechanisms including slowing gastric emptying, reducing hepatic glucose production, and enhancing insulin secretion in a glucose-dependent manner.
When you buy tirzepatide for research purposes, you receive a high purity compound that has been rigorously tested for quality and consistency. The white lyophilized powder form ensures stability and ease of handling in laboratory settings.
For researchers investigating metabolic pathways or potential therapeutic applications, tirzepatide offers a unique pharmacological profile. Its dual mechanism of action distinguishes it from single receptor agonists and may provide insights into more effective approaches to metabolic regulation.
Our facility produces tirzepatide under strict quality control measures, ensuring researchers receive material that meets exacting standards. The compound is provided for laboratory investigation only and is not intended for human consumption.